Featured Research

from universities, journals, and other organizations

Stanford Researchers Study Emerging Treatment For Chronic Sinus Infections

Date:
December 27, 2002
Source:
Stanford University Medical Center
Summary:
Conducted over 12 months beginning in November 2000, the study is the first to prospectively evaluate the effectiveness of nebulized antibiotics for the treatment of chronic sinusitis following surgery. Results are published in the December issue of Otolaryngology, Head and Neck Surgery.

STANFORD, Calif. Three years ago, Joanne Clark was so miserable from recurring sinus infections and the antibiotics used to treat them that she felt ready to give up. Despite three surgeries, Clark, a resident of Lodi, Calif., continued getting sinus infections every two to four weeks. The painful headaches and feelings of exhaustion, not to mention the severe nausea from oral antibiotics, forced her to quit her job as a physical education teacher. "I felt horrible," she said. "I had headaches all the time. I had no energy. I didn"t want to live a life like this."

Clark eventually came to Stanford Hospital & Clinics where Winston Vaughan, MD, an otolaryngologist, sinus surgeon and director of the Stanford Sinus Center, suggested she participate in a clinical trial of an innovative new treatment. Instead of taking antibiotics in a pill, Clark could breathe them into her sinuses using a nebulizer - a machine that converts medication from a liquid into an inhalable mist.

Conducted over 12 months beginning in November 2000, the study is the first to prospectively evaluate the effectiveness of nebulized antibiotics for the treatment of chronic sinusitis following surgery. Results are published in the December issue of Otolaryngology, Head and Neck Surgery.

After taking the nebulized antibiotics twice daily for three weeks, Clark experienced significant relief. Her symptoms including headaches, congestion and fatigue subsided more quickly than with antibiotic pills, and she remained infection-free far longer - nearly three months. While she experienced some mild side effects, "it was nothing compared with the pills." Most of the other study participants saw similar benefits from nebulized antibiotics. Of the 42 patients studied - all adults who suffered recurrent sinus infections after surgery - 76 percent reported "significant improvement" in symptoms, confirmed through physical exams and sinus endoscopies.

Significantly, the patients who benefited from the treatment remained free of infection for an average of 17 weeks, compared with six weeks previously. Like Clark, they reported few side effects and improved quality of life.

Based on these results, Vaughan believes nebulized antibiotics represent a promising alternative for patients who continue getting sinus infections even after surgery and who have failed, or cannot tolerate, oral or intravenous antibiotics. "These results are very encouraging," said Vaughan, assistant professor of surgery at the School of Medicine and lead author of the study. Nebulized antibiotics "may serve as a new treatment option in an often frustrating disease process."

Sinusitis affects 35 million Americans, making it the country's most prevalent chronic condition, according to the Centers for Disease Control and Prevention. As Clark"s experience shows, the condition can significantly reduce productivity and quality of life.

"These patients feel miserable," Vaughan said. "They have facial pain, they can't breathe and they can't sleep." Nebulized antibiotics, he said, were developed in the late 1990s "out of a desperate need for something else."

While asthma patients have long relied upon nebulizers to inhale medication into their lungs, the use of nebulized antibiotics to treat sinus infections emerged only in the last two to three years.

Why does the treatment work so well? "The common-sense answer is, we're getting more of the medication directly to the tissues that need it" because the medication is inhaled into the nostrils instead of circulating through the entire body, Vaughan said. He added that more research is needed to understand exactly how the treatment works.

Vaughan chairs the scientific advisory board of SinusPharmacy Corp., a company that formulates nebulized antibiotics and other medications to treat sinus infections. The company"s medications were used in the Stanford study. All data from the study were analyzed independently of the company. The research was funded solely by Stanford University Medical Center.

Clark, for her part, still gets sinus infections three to four times a year, but she said the episodes are far more manageable with nebulized antibiotics. Because her health has improved, she has returned to work at the school district.

"I feel great most of the time," Clark said. "I tell people this treatment gave me my life back."

###

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "Stanford Researchers Study Emerging Treatment For Chronic Sinus Infections." ScienceDaily. ScienceDaily, 27 December 2002. <www.sciencedaily.com/releases/2002/12/021227070722.htm>.
Stanford University Medical Center. (2002, December 27). Stanford Researchers Study Emerging Treatment For Chronic Sinus Infections. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2002/12/021227070722.htm
Stanford University Medical Center. "Stanford Researchers Study Emerging Treatment For Chronic Sinus Infections." ScienceDaily. www.sciencedaily.com/releases/2002/12/021227070722.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins